Cancer News and Research

Latest Cancer News and Research

Clinical Care Options to provide online continuing medical education in "The Oncology Portal"

Clinical Care Options (CCO), a leader in the development of innovative interactive online, print, and live medical education for healthcare professionals, today announced its exclusive collaboration with Oncology Today(TM), a wholly owned subsidiary of US Oncology, Inc., to be the provider of online continuing medical education (CME) for the newly formed US Oncology's online clinician community, "The Oncology Portal."

13 Nov 2009

Mechanical ventilation damages lungs, says scientist

As more Canadians are diagnosed with H1N1 influenza infection, some will be admitted to hospital. The most severely affected may be treated in the intensive care unit (ICU) and placed on a mechanical ventilator to help them breathe while they recover from the infection.

13 Nov 2009

Breast cancer patients who undergo fertility preservation need not delay treatment

A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion.

13 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

PDL BioPharma to pay $200 million special dividend payment to stockholders

PDL BioPharma, Inc. (PDL) today announced that it will pay a $200 million special dividend to stockholders, with part of the proceeds from the $300 million securitization transaction completed on November 2, 2009.

13 Nov 2009

BioInvent International, Daiichi Sankyo sign licence and discovery agreement

BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

13 Nov 2009

New gene therapy may breach the armor of cancerous tumors

The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Researchers at the Cornell University College of Veterinary Medicine have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- a gene mutated in the majority of human cancers.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

New and effective medicines underway for treating a wide range of diseases affecting women

Women's Health Weekly recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

13 Nov 2009

Innomed/BioRobotics to be Health Robotics' exclusive strategic partner in Korea

Health Robotics today announced that Innomed/BioRobotics, on the heels of its prior market success with Oncology Surgery robots, has exclusively selected Health Robotics' CytoCare(TM) Robot to reach its objective to become the gold standard for Oncology Robotics IV Admixtures in the Republic of Korea and synergistically provide an end-to-end Cancer Robotics solution.

13 Nov 2009

Peplin merges with LEO Pharma

Peplin, Inc. today announced that it has completed its merger with LEO Pharma A/S (LEO) after obtaining the approval of the majority of Peplin stockholders. The deal was originally announced on 3 September, 2009 when LEO, a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, agreed to acquire all outstanding securities of Peplin for approximately US$287.5 million in cash. The merger consideration will be distributed to holders of common stock and CDIs promptly.

13 Nov 2009

Cancer patients with dense breasts have a higher risk of recurring malignancy

A study published in the current issue of Cancer found that breast cancer patients with dense breasts have a 4x higher risk of recurring malignancy.

13 Nov 2009

New findings on human genome may be useful for developing specific AIDS drugs

The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

LA BioMed to participate in a national study of the effectiveness of testosterone

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it will participate in a large national study of the effectiveness of testosterone as a treatment for anemia, cardiovascular disease, decreased vitality, impaired memory and sexual function, loss of muscle mass and other health conditions that affect older men.

13 Nov 2009

CMS approves FDG PET for initial staging of cervical cancer

SNM applauds the Centers for Medicare & Medicaid Services- (CMS) decision to expand coverage of FDG PET for the initial staging of cervical cancer without previously imposed restrictions.

13 Nov 2009

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Ipsen, an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.

13 Nov 2009

RERF awarded $9.7M to study the effects of atomic bomb radiation and aging on the human immune system

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded nearly $9.7 million over five years to the Radiation Effects Research Foundation (RERF), Japan, to study the effects of atomic bomb radiation and aging on the human immune system.

13 Nov 2009

Mouth: A diagnostic indicator for general health

The mouth or oral cavity area is an excellent indicator of the whole body's health, says Mao, who is the chair of the new Department of Oncology and Diagnostic Sciences at the School.

13 Nov 2009

EDDA Technology recieves CE Mark for its IQQA-Liver advanced clinical application

EDDA Technology today announced the completion of CE mark for its new release of IQQA®-Liver, an advanced clinical application designed to enhance efficiency and precision in liver imaging evaluation and treatment planning.

13 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Clinical Care Options to provide online continuing medical education in "The Oncology Portal"

Mechanical ventilation damages lungs, says scientist

Breast cancer patients who undergo fertility preservation need not delay treatment

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

PDL BioPharma to pay $200 million special dividend payment to stockholders

BioInvent International, Daiichi Sankyo sign licence and discovery agreement

New gene therapy may breach the armor of cancerous tumors

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

New and effective medicines underway for treating a wide range of diseases affecting women

Innomed/BioRobotics to be Health Robotics' exclusive strategic partner in Korea

Peplin merges with LEO Pharma

Cancer patients with dense breasts have a higher risk of recurring malignancy

New findings on human genome may be useful for developing specific AIDS drugs

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

LA BioMed to participate in a national study of the effectiveness of testosterone

CMS approves FDG PET for initial staging of cervical cancer

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

RERF awarded $9.7M to study the effects of atomic bomb radiation and aging on the human immune system

Mouth: A diagnostic indicator for general health

EDDA Technology recieves CE Mark for its IQQA-Liver advanced clinical application

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in